News

Dr Jochelson and Mr Levin will serve in integral roles managing clinical programs and licensing/partnership agreements for BrainCells’s pipeline of neurologic compounds. Dr Jochelson will replace Steve Targum

A previous licensing agreement covering Europe, Russia, the Middle East, North Africa, Latin America and Canada was signed in January 2009. Under the terms of the agreement, EffRx

Mr Whitnell will work in this capacity under the oversight of the special committee of the board of directors until a new CEO is named. As the company

Gilead Sciences, a biopharmaceutical company, has started enrolling patients in a Phase II clinical trial of cicletanine hydrochloride, an oral agent in development for the treatment of pulmonary

The alliance seeks to increase productivity in drug discovery and development by synergizing the unique strengths of both companies. The collaborative research program may continue for a span

Mr Hamm has been executive vice president of pharmaceutical operations and technology at the company since 2007. As COO, Mr Hamm will add global business operations to his

Ligand Pharmaceuticals, a biotechnology company, has reported that its partner, Pfizer has received approval from the European Commission for Fablyn tablets, a selective estrogen receptor modulator for the

HemCon Medical Technologies, a developer of advanced medical products, has announced improved results from an independent study investigating the time required to successfully treat fungal infected human nails

Vertex Pharmaceuticals, a biotechnology company, has initiated a Phase IIa clinical trial for VX-809, an investigational cystic fibrosis transmembrane conductance regulator corrector that targets the defective CFTR protein